
    
      This is a phase I study of GSK1223249. The study design is randomized, placebo-controlled,
      double-blind, sequential dose escalation, single dose administration. Approximately 36
      patients with relapsing forms of Multiple Sclerosis (having had at least two relapses over
      the previous 24 months, OR at least one relapse within the last 12 months, OR having had at
      least one documented gadolinium-enhancing lesion on brain magnetic resonance imaging (MRI)
      within 12 months prior to Screening) will be enrolled.
    
  